Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

Clinical trial NCT05280314 · RECRUITING

Trial details

NCT number: NCT05280314
Sponsor: IO Biotech
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Melanoma Squamous Cell Carcinoma of Head and Neck

Start date: 2023-12-21
Primary completion: 2025-04-30
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.